DK0759295T3 - Anvendelse af adamantan-derivater til behandling af tinnitus - Google Patents

Anvendelse af adamantan-derivater til behandling af tinnitus

Info

Publication number
DK0759295T3
DK0759295T3 DK96112325T DK96112325T DK0759295T3 DK 0759295 T3 DK0759295 T3 DK 0759295T3 DK 96112325 T DK96112325 T DK 96112325T DK 96112325 T DK96112325 T DK 96112325T DK 0759295 T3 DK0759295 T3 DK 0759295T3
Authority
DK
Denmark
Prior art keywords
adamantane derivatives
treat tinnitus
alkyl
tinnitus
treat
Prior art date
Application number
DK96112325T
Other languages
English (en)
Inventor
Hans Peter Prof Dr Med Zenner
J Peter Prof Dr Ruppersberg
Original Assignee
Tinnitus Forschungs Und Entwic
Hans Peter Prof Dr Med Zenner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tinnitus Forschungs Und Entwic, Hans Peter Prof Dr Med Zenner filed Critical Tinnitus Forschungs Und Entwic
Application granted granted Critical
Publication of DK0759295T3 publication Critical patent/DK0759295T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
DK96112325T 1995-08-02 1996-07-31 Anvendelse af adamantan-derivater til behandling af tinnitus DK0759295T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19528388A DE19528388A1 (de) 1995-08-02 1995-08-02 Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs

Publications (1)

Publication Number Publication Date
DK0759295T3 true DK0759295T3 (da) 1999-01-25

Family

ID=7768513

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96112325T DK0759295T3 (da) 1995-08-02 1996-07-31 Anvendelse af adamantan-derivater til behandling af tinnitus

Country Status (14)

Country Link
US (1) US6066652A (da)
EP (2) EP0834310A1 (da)
JP (1) JP3568039B2 (da)
KR (1) KR100393296B1 (da)
CN (1) CN1142775C (da)
AT (1) ATE163545T1 (da)
AU (1) AU719018B2 (da)
BR (1) BR9609950A (da)
DE (3) DE19528388A1 (da)
DK (1) DK0759295T3 (da)
ES (1) ES2116801T3 (da)
IL (1) IL123142A (da)
PL (1) PL324795A1 (da)
WO (1) WO1997004762A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6649621B2 (en) * 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
DE19807426A1 (de) 1998-02-23 1999-10-14 Otogene Biotechnologische Fors Verfahren zur Behandlung von Erkrankungen oder Störungen des Innenohrs
US7132406B2 (en) 1998-02-23 2006-11-07 Sound Pharmaceuticals Incorporated Stimulation of cellular regeneration and differentiation in the inner ear
AU5170400A (en) * 1999-05-27 2000-12-18 George F. El Khoury Topical application of muscarinic and opioid agents for treatment of tinnitus
US6444702B1 (en) * 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
WO2002012067A1 (en) * 2000-08-08 2002-02-14 International Paper Company Process for activating oxygen scavenger components during a gable-top carton filling process
EP1201234A3 (en) * 2000-09-21 2003-03-12 Tinnitus Forschungs- und Entwicklungs GmbH Treatment of diseases with adamantane derivates
EP1190711A1 (en) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Treatment of diseases with adamantane derivatives
EP1190709A1 (en) * 2000-09-21 2002-03-27 Tinnitus Forschungs- und Entwicklungs GmbH Treatment of tinnitus
JPWO2002030418A1 (ja) 2000-10-13 2004-02-19 中外製薬株式会社 脂質代謝改善用組成物
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US7795468B2 (en) * 2001-01-19 2010-09-14 Chevron U.S.A. Inc. Functionalized higher diamondoids
US20030191064A1 (en) * 2001-01-23 2003-10-09 Kopke Richard D. Methods for preventing and treating loss of balance function due to oxidative stress
EP1545551A4 (en) * 2002-09-06 2008-10-22 Durect Corp DISTRIBUTION OF MODULATORS OF THE GLUTAMAT-MEDIATED NEUROTRANSMISSION TO THE INNER EAR
US8268866B2 (en) * 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US20060063802A1 (en) * 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US9072662B2 (en) 2004-03-29 2015-07-07 Auris Medical Ag Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8349359B2 (en) 2004-11-07 2013-01-08 Your Energy Systems, LLC Liposomal formulation for oral administration of glutathione (reduced)
US7619007B2 (en) 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
US20060211650A1 (en) * 2004-12-16 2006-09-21 Forest Laboratories, Inc. Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof
EP1861161A4 (en) * 2005-01-24 2012-05-16 Neurosystec Corp APPARATUS AND METHOD FOR DISPENSING THERAPEUTIC AND / OR OTHER AGENTS IN THE INTERNAL EAR AND OTHER FABRICS
DE102005004343A1 (de) * 2005-01-25 2006-08-10 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung von Phantomphänomenen
EP1861104A4 (en) * 2005-03-04 2011-12-14 Neurosystec Corp IMPROVED GACYCLIDINE FORMULATIONS
WO2006121560A2 (en) 2005-04-06 2006-11-16 Adamas Pharmaceuticals, Inc. Methods and compositions for treatment of cns disorders
US20070021352A1 (en) * 2005-07-20 2007-01-25 Cypress Bioscience, Inc. Prevention and treatment of hearing disorders
DK1928405T3 (da) 2005-09-28 2014-12-15 Auris Medical Ag Farmaceutiske sammensætninger til behandling af indre øreforstyrrelser
US8267905B2 (en) * 2006-05-01 2012-09-18 Neurosystec Corporation Apparatus and method for delivery of therapeutic and other types of agents
US7803148B2 (en) * 2006-06-09 2010-09-28 Neurosystec Corporation Flow-induced delivery from a drug mass
WO2008011125A2 (en) * 2006-07-20 2008-01-24 Neurosystec Corporation Devices, systems and methods for ophthalmic drug delivery
CA2659330A1 (en) * 2006-07-31 2008-02-07 Neurosystec Corporation Nanoparticle drug formulations
US20080065002A1 (en) * 2006-09-07 2008-03-13 Neurosystec Corporation Catheter for Localized Drug Delivery and/or Electrical Stimulation
US20100129467A9 (en) * 2007-08-31 2010-05-27 Albritton Iv Ford D Nutritional supplement
CN101801365A (zh) * 2007-09-12 2010-08-11 莫茨药物股份两合公司 治疗耳鸣的间隔疗法
TW201010691A (en) * 2008-06-12 2010-03-16 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexane derivatives for the treatment of sleep disorders
US8454877B2 (en) * 2009-04-03 2013-06-04 Pelican Products, Inc. Method and apparatus for molding an article
BR112012013487A2 (pt) 2009-12-02 2017-10-03 Adamas Pharmaceuticals Inc Composições de amantadina e métodos de uso
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
ES2862673T3 (es) 2011-12-12 2021-10-07 Zilentin AG Tratamiento del tinnitus mediante la modulación del cotransportador de cloruro NKCC1 en el sistema auditivo
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
LT3313879T (lt) 2015-06-24 2022-03-25 F. Hoffmann-La Roche Ag Antikūnai prieš transferino receptorių su pritaikytu giminingumu
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
TWI819458B (zh) 2015-10-02 2023-10-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3328251A (en) * 1965-12-30 1967-06-27 Du Pont Pharmaceutical compositions and methods utilizing 2-aminoadamantane and its derivatives
US4331686A (en) * 1981-08-28 1982-05-25 Pennwalt Corporation Treatment of otitis externa in dogs with beta-(1-adamantyl)-alpha,alpha-dimethylethylamine
DE10299048I2 (de) * 1989-04-14 2006-07-13 Merz Pharma Gmbh & Co Kgaa Verwendung von Adamantan-Derivaten zur Pr{vention und Behandlung der cerebralen Isch{mie
DE3921062A1 (de) * 1989-06-23 1991-01-03 Lange Werner Therapie und prophylaxe von infektionen mit retroviren mit 1-adamantanamin hydrochlorid (amantadin) allein oder in kombination mit anderen antiviralen substanzen
DE4014672A1 (de) * 1990-05-08 1991-11-14 Werner E G Prof Dr Mueller Verwendung von adamantan-derivaten zur zytoprotektion von nicht-infizierten und virus-infizierten lymphozyten als auch anderen zelltypen

Also Published As

Publication number Publication date
IL123142A0 (en) 1998-09-24
KR19990036073A (ko) 1999-05-25
EP0834310A1 (de) 1998-04-08
WO1997004762A1 (de) 1997-02-13
MX9800925A (es) 1998-10-31
EP0759295B1 (de) 1998-03-04
AU719018B2 (en) 2000-05-04
CN1142775C (zh) 2004-03-24
JP2000515486A (ja) 2000-11-21
ATE163545T1 (de) 1998-03-15
KR100393296B1 (ko) 2003-11-17
PL324795A1 (en) 1998-06-22
BR9609950A (pt) 1999-06-29
DE19528388A1 (de) 1997-02-06
ES2116801T3 (es) 1998-07-16
JP3568039B2 (ja) 2004-09-22
AU6788296A (en) 1997-02-26
IL123142A (en) 2001-10-31
EP0759295A1 (de) 1997-02-26
DE59600105D1 (de) 1998-04-09
US6066652A (en) 2000-05-23
DE19680619D2 (de) 1998-10-29
CN1194581A (zh) 1998-09-30

Similar Documents

Publication Publication Date Title
DK0759295T3 (da) Anvendelse af adamantan-derivater til behandling af tinnitus
DE60037892D1 (de) Nitroimidazolpräparationen zur äusseren anwendung zur behandlung von atopischer dermatitis
NZ332762A (en) Isobutylgaba and its derivatives for the treatment of pain
DE69615558T2 (de) Zns-aktive semicarbazone und diese enthaltende pharmazeutische zubereitungen
ATE183183T1 (de) Indol-, indazol- und benzisoxazolderivate zur behandlung von schizophrenia
ES2148561T3 (es) Prevencion y curacion de enfermedades alergicas de tipo i.
ES2094545T3 (es) Derivados n-substituidos del 3-azabiciclo(3.2.0)heptano, como neurolepticos etc..
PT783495E (pt) Derivados de quinoxalina uteis em terapia
ATE223379T1 (de) N-aryloxyethylaminderivate zur behandlung der depression
DK0623131T3 (da) Alkylderivater af trazodon med CNS-aktivitet
CO5040091A1 (es) Derivados de urea
DE69619088T2 (de) Quinoxalin-Derivate zur Behandlung von Tinnitus
DE60005525D1 (de) 2-aminotetraline zur behandlung von glaukom
ATE186912T1 (de) Carbamoylpyrrolidon-derivate zur behandlung von depressionen und cerebrovasculären störungen
DK0877612T3 (da) Anvendelse af piperazinderivater til behandling af cognitive forstyrrelser
DK0667860T3 (da) Azaspiroalkan-derivater som terapeutiske midler